Annexon’s failure in geographic atrophy could clear the way for its rivals.
The FTC moves to block Amgen’s Horizon takeout, broadening its remit to curb anticompetitive moves that inflate drug prices.
Alzheimer’s has already grabbed attention but plenty of big regulatory decisions still loom for Sarepta, Crispr, Astellas and more.
In purchasing Iveric for $5.9bn the Japanese group has plumped for the cheaper geographic atrophy player.
US Pdufa decisions loom for Apellis and Travere, while Menarini and Lilly got their approval firsts already.
NGM’s NGM621 now looks like a dead end, but there are plenty of others hoping for a piece of this market, including Roche and Lineage.
But data from Gather2 do not look as impressive as earlier results.